Rosiglitazone reduces fatty acid translocase and increases AMPK in skeletal muscle in aged rats: a possible mechanism to prevent high-fat-induced insulin resistance.
Song
Guang-yao
GY
Department of Endocrinology, General Hospital of Hebei Province, Shijiazhuang, Hebei 050051, China. sguangyao@sohu.com
Gao
Yu
Y
Wang
Chao
C
Hu
Shu-guo
SG
Wang
Jing
J
Qu
Dong-ming
DM
Ma
Hui-juan
HJ
D055372:AMP-Activated Protein Kinases / Q000235:genetics*; D000103:Acetyl-CoA Carboxylase / Q000235:genetics; D000818:Animals; D018955:CD36 Antigens / Q000235:genetics*; D004041:Dietary Fats / Q000008:administration & dosage*; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance; D008297:Male; D018482:Muscle, Skeletal / Q000201:enzymology*; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017208:Rats, Wistar; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology*
D018955:CD36 Antigens; D004041:Dietary Fats; D007004:Hypoglycemic Agents; D012333:RNA, Messenger; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D055372:AMP-Activated Protein Kinases; D000103:Acetyl-CoA Carboxylase